Aligos Therapeutics Inc (ALGS)

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the...

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a...

Form 8-K - Current report

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results

SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS...

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS...

Form 8-K - Current report

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones...

Form 8-K - Current report

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation

Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus...

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans